1-3 of 3
Wilhelm Oberaigner
Close
Sort by
Journal Articles

Non-Pegylated Liposomal Encapsulated Doxorubicin Reduces Cardiotoxicity in 1st Line Treatment of Diffuse Large B-Cell Lymphoma (DLBCL). Final Results of a Randomized Trial

Michael A. Fridrik, MD, Andreas L Petzer, M.D., Felix Keil, MD, Wolfgang Willenbacher, MD, Ulrich Jaeger, MD, Alois Lang, MD, Sonja Burgstaller, MD, Johannes Andel, MD, Otto Krieger, M.D., Wilhelm Oberaigner, Richard Greil, MD
Journal: Blood
Blood (2011) 118 (21): 2676.
https://doi.org/10.1182/blood.V118.21.2676.2676
Published: 2011
Journal Articles

Is Liposome Encapsulated Doxorubicin Able to Reduce the Cardiotoxicity of Doxorubicin In the Treatment of DLBCL? A Randomised Study by the Austrian Working Party of Medical Oncology (AGMT-study NHL-14)

Michael Fridrik, MD, Andreas L Petzer, MD, Felix Keil, MD, Wolfgang Willenbacher, MD, Ulrich Jäger, MD, Alois Lang, MD, Johannes Andel, MD, Otto Krieger, MD, Wilhelm Oberaigner, Richard Greil, MD
Journal: Blood
Blood (2010) 116 (21): 1766.
https://doi.org/10.1182/blood.V116.21.1766.1766
Published: 2010
Journal Articles

Molecular Remission after Induction Chemo- Immunotherapy and Rituximab Maintenance in Previously Untreated Follicular Lymphoma.

Michael A Fridrik, MD, Richard Greil, Georg Hopfinger, MD, Christine Mannhalter, Wilhelm Oberaigner, Ulrich Jaeger, MD
Journal: Blood
Blood (2009) 114 (22): 2724.
https://doi.org/10.1182/blood.V114.22.2724.2724
Published: 2009